.

The results of our annual People Experience Survey are in and we’re proud of the progress we’ve made on our culture journey! More than 4,500 employees—approximately 86% of our workforce—shared their thoughts on what our culture is doing well and where we can do even better. Our engagement score, two points above the external benchmark, shows us that we are on track in our ambition to embed a culture of collaboration, excellence and impact across Ipsen. 

Our strong sense of purpose, clear values, commitment to embedding diversity, equity and inclusion into our workplace and our Generation Ipsen sustainability strategy push us to deliver a more sustainable, healthier and better future, at Ipsen, for the patients we serve and for society as a whole. 

To learn more about our culture, visit our Culture page HERE. 

*Our People Experience Survey is managed and run through our external provider who ensures the confidentiality of the answers and provides the external benchmark   

“If this podcast encourages even one listener to get checked and catch cancer early, it’s worth every word.” 

Ipsen’s Get Men Talking Podcast returns with a second episode for Movember 2024, continuing to urge men to get screened for prostate cancer and prioritise their long-term health. This year’s episode brings you a candid, heartfelt discussion with Tim Batchelor, now celebrating over 10 years cancer-free, and his Urologist, Mr Simon Bott, who’s been by his side every step of the way. 

Tim reflects on his early diagnosis at age 48, a pivotal decision that led to an early and successful treatment. Simon adds a thoughtful medical perspective, underscoring the importance of early screening for men approaching 50, who might be at risk but otherwise symptom-free. Together, they paint a picture of what a trusting, supportive patient-physician relationship can achieve, bringing moments of humour with heartfelt honesty. 

This is more than a conversation—it’s an invitation to every man to think about his health and his future. It’s never too early to start the conversation or book that check-up. Early diagnosis often means less intensive treatment, quicker recovery, and the ability to keep living life to the fullest. 

If we can encourage even one listener to get checked and catch cancer early, it’s worth every word. So listen in, reflect on Tim and Simon’s conversation, and, most importantly, take a moment to prioritize your health. Don’t wait for symptoms; get screened and stay informed. 

Tune in today—it could be the conversation that saves a life. 

Get Men Talking – an insight into prostate cancer from a patient and his Urologist

Get Men Talking Podcast – Tim’s story with prostate cancer

David Jenkins, SVP and Head of External Innovation and Research, leads efforts to identify, evaluate and secure new programs across Ipsen’s three strategic areas of Oncology, Rare disease, and Neuroscience. He shares his insights on the essential role that collaboration, strategic partnerships, and a science-driven approach play in delivering scientific breakthroughs for patients.

Scientific innovation thrives on collaboration. From the global effort behind the Human Genome Project to the Nobel Prize-winning discoveries of Richard J. Roberts and Phillip A. Sharp whose research on split genes aided the understanding of some rare diseases — teamwork has consistently driven major breakthroughs. At Ipsen, this principle is particularly vital, as we are building our pipeline exclusively through external partnerships. This strategic choice allows us to work alongside some of the best innovators in life-sciences to deliver life-changing treatments to patients. 

Our external innovation strategy is guided by three core principles: being science driven, prioritizing patient impact, and focusing on precision medicine. With this in mind, our bar is set to best- or first-in-class innovation supported by compelling scientific rationale within our three focus areas: Oncology, Rare disease, and Neuroscience. The foundation of this strategy is built on strong collaboration, which allows us to leverage our united expertise to achieve a shared scientific vision. By focusing on precision medicine and targeting niche areas of disease with high unmet medical needs, we aim to make a significant impact on underserved populations. Our execution of biomarker-driven clinical trials allows us to swiftly identify efficacy signals and make data-driven decisions to accelerate the advancement of the most promising assets.

Our collaborative approach combines the strengths of both Ipsen and our partners, pushing the boundaries beyond what we could achieve separately. Our partners bring strong science and a deep understanding of their therapy areas of focus, throughout the development process. We contribute our expertise in translational, CMC (Chemistry, Manufacturing, and Controls), global clinical development and regulatory. Together, we continue to build a balanced portfolio between established and emerging areas of science, striking the right balance between risk and ability to deliver proof of concept in early clinical development. By maintaining a mix of novel and established modalities in our expanding pipeline, we are well-positioned to advance transformative treatments.

Ipsen’s commitment to collaboration drives our innovation and ensures we are consistently at the forefront of delivering breakthrough therapies to those who need them most. By continually refining our focus and working hand-in-hand with leading innovators, we are not just advancing our pipeline – we are paving the way for the next generation of breakthrough therapies that will transform the lives of patients worldwide.

By partnering with others who share your vision and complement your strengths, you can unlock new possibilities that would have been impossible alone. When will you next seek a partnership that pushes boundaries? 

Ipsen is proud to announce that 12 countries have been certified as a Great Place to Work in 2024. With that we are now considered as employer of choice in a total of 28 countries worldwide. This significant achievement reflects the collaborative spirit and dedication of our employees. Also, Fortune Magazine, in partnership with Great Place to Work, published the list of Fortune’s 100 Best Companies to Work For in Europe™. Not only did Ipsen make this prestigious list, but we are ranked #25, a testament to our strong company culture and commitment to creating a workplace where people can thrive.

A culture rooted in Collaboration, Excellence and Impact

Desktop Image

A culture rooted in Collaboration, Excellence and Impact

At Ipsen, our people are at the core of everything we do. We believe that fostering a culture of collaboration, excellence and impact is essential to achieving our mission of improving patients’ lives and contributing to a better society. Our employees go above and beyond every day, bringing passion, innovation, and dedication to their roles. It is this collective commitment that has enabled us to build a friendly and safe environment where everyone can succeed and feel supported.

Régis Mulot Profile

“These recognitions are an immense pride for us. This achievement is a direct reflection of our incredible people, whose passion and determination make Ipsen a special place to work. We are committed to maintaining and enhancing this culture as we continue to grow and make a meaningful impact on society and the patients we serve.”

Régis Mulot

EVP and Chief Human Resources Officer at Ipsen

The recognition by Fortune Magazine and Great Place to Work marks a new chapter in our ongoing journey to make Ipsen not just a company, but a community where people feel inspired to push boundaries, deliver results, and make a real impact every day. Thank you to all Ipsen employees for making this achievement possible. Together, we will continue to strive for greatness.

*Accredited countries: Algeria, Australia, Austria, Belgium, Brazil, Canada, China, Colombia, Czechia, France, Germany, Greece, Hungary, Italy, Ireland, Kazakhstan, Lithuania, Mexico, Netherlands, Poland, Russia, Singapore, Spain, Sweden, Switzerland, United Arab Emirates, United States of America and United Kingdom

The United Nations Global Compact is a voluntary initiative that calls on CEOs worldwide to implement universal sustainability principles and support the United Nations (UN) goals. By joining the UN Global Compact, companies commit to aligning their strategies and operations with ten fundamental principles in the areas of human rights, labor, environment, and anti-corruption, while also contributing to broader societal objectives. 

We, at Ipsen, take great pride in our ongoing support of the United Nations Global Compact (UNGC), a commitment we have upheld since 2012. This year, we have once again renewed our pledge with the submission of our letter of commitment and completed the 2024 questionnaire.  Our sustainable growth strategy, embodied by Generation Ipsen and aligned with the sustainable development goals, unites our efforts across our four pillars:  

Through our Generation Ipsen sustainability strategy, we’re not just shaping a future we can be proud of, we’re making a positive impact today. Together, we’re building a better world for generations to come. 

Press Release

The financial results have been published and a conference call will take place at 14H00 CET.

Webcast details

Webcast details

Webcast replay
Q&A Audio Call details

Q&A Audio Call details

A conference call will take place at 14H00 CET.

Register now

We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience.rnrnOur pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries.rnrnIpsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY).

IPSEN IN BRIEF

Our vision is to be a leading global mid-sized biopharmaceutical company with a focus on transformative medicines in Oncology, Rare Disease and Neuroscience.rnrnDiscover Ipsen in two pages; our products and key figures, our objectives and our strategy.

Download Ipsen in brief
Alert

If you are experiencing difficulties registering for the investor and analyst conference call, please contact: nicolas.bogler@ipsen.com

.

Meeting the world’s highest standard for operational excellence is rare, and it’s even rarer to do it twice. Ipsen’s manufacturing site in Signes first received the Shingo Prize for operational excellence in 2020. Now our Dublin manufacturing site has earned a Shingo Prize, as well, making Ipsen the first pharmaceutical company to receive two Gold Shingo Prizes. Our Wrexham, U.K. manufacturing site currently holds a Shingo Bronze Medallion award. 

Created in 1988, the Shingo Prize rewards companies across all sectors that demonstrate a strong culture of operational excellence, deeply rooted in the mindset and behaviors of all staff, management and employees alike.

“It’s exciting to see how the Shingo Model™ can be implemented successfully across different sites, in different countries and cultures,” said Aidan Murphy, EVP Technical Operations. “The Dublin teams incorporated learnings from the Signes site, while also bringing their own perspective and innovations to the table. We’re looking forward to implementing the Shingo Guiding Principles at other Ipsen sites, and continuing our journey of operational excellence.” 

The Shingo examination team conducted a rigorous assessment of the Dublin site, including its employees, processes and mindset, which took place in July 2024. But the ambition to receive a Shingo Prize began long before. “The journey to excellence in our manufacturing sites began in 2015, almost a decade ago,” noted Pierrick Lefranc, Senior Vice President, Head of Global Manufacturing Operations. “I’m really proud of the exceptional level of engagement of all the teams on site,” he continued. “The Shingo Model places a strong emphasis on employee engagement: as a result, every employee understands our strategy and how their daily actions impact it. It’s a powerful illustration of our culture of excellence and impact.” 

Ipsen’s Dublin manufacturing site houses approximately 190 people and produces the active pharmaceutical ingredients for two of Ipsen’s medicines. 

.

Sustainability plays a critical role in shaping the future of our business and the world at large. To ensure we embed sustainability in our supply chain, we recently hosted our inaugural Supplier Sustainability Day event, bringing in key partners to meet with Ipsen leaders.  

This event provided an opportunity to share best practices and discuss how we can collaborate to create more responsible and sustainable supply chains.  

Key Highlights  

The event culminated in a commitment to deepen collaboration and establish a clear path toward a more sustainable future.  

Explore some of the key moments from the event below:

We look forward to continuing our journey towards a greener and more responsible future, in partnership with our valued suppliers.  

A few months after Eva Luna was born, her mother Francesca realized something wasn’t quite right. Within the span of a few days, their world was turned upside down when her daughter was diagnosed with a rare liver disease, known as Progressive Familial Intrahepatic Cholestasis (PFIC). Francesca describes her daughter as her “miracle” Eva Luna, now five, is thriving, dancing, and recently started school.  

IIn the first weeks after Eva Luna was born, everything was fine. “And then when she turned two and half months old, something changed in the color of her eyes and her skin, and she had a lot of diarrhea.” This prompted a trip to the Emergency Department, where within two days the doctors spoke the words that would change Eva Luna’s life forever; “I think it’s Progressive Familial Intrahepatic Cholestasis.”  

Francesca describes that after the initial shock of her daughter’s diagnosis, she fell into a period of depression, and she couldn’t take care of Eva Luna for the first few months following the diagnosis. During this time, her husband Simone kept their family going and kept Eva Luna smiling. 

PFIC is a rare liver disease that can pose significant challenges, particularly in young children. This spectrum of genetic disorders causes a build-up of bile in the liver. If left untreated, PFIC can lead to end-stage liver failure and require a liver transplant.

Following a successful surgery, known as an internal biliary diversion, Eva Luna’s itch became more manageable, and this was life changing. “She now has the chance to go to school, to dance, and do everything.” 

“When she was growing, her itch was growing. Her itch was eating away at our life, like a monster.” – Francesca 

Eva Luna’s diagnosis and treatment had a life-changing impact on the whole family, including her brother Ernesto, who is five years older. Siblings of children with rare diseases often face emotional challenges of their own, feeling isolation, anxiety, and confusion about the attention their sibling receives.  

But that doesn’t mean they aren’t also a source of strength. “The biggest medicine against the itch is to keep her busy in activities. This is something that Ernesto understood first. They play a lot together; they fight a lot together. She needs him close to her, more than me or her father.” Their bond is one of love, laughter, and resilience: a reminder that siblings are often sources of strength in families living with rare disease. 

Francesca’s experiences as a caregiver highlighted to her how vital connection and community can be: “It was very important to me to be in touch with the other mothers around the world. It gave me a lot of hope, because I saw their children grow, go to school and even have a normal life.” The association PFIC Italia Network was created for this reason, to ensure that families experiencing rare liver disease do not feel alone. 

“I promised to myself that since something like that has happened to us, I have to use all my energy to help other mothers not feel so alone.”  

To learn more about PFIC, visit the PFIC Network’s website here: https://www.pfic.org  

.

We are proud to announce that Ipsen’s rating has reached an all-time high in the 2024 S&P Global Corporate Sustainability Assessment (CSA). Our score has increased by 4 points, from 57 in 2023 to 61 as of 19 September 2024, placing Ipsen in the 94th percentile of our industry. This remarkable achievement reflects our unwavering commitment to sustainability, transparency, and continuous improvement. 

The Importance of S&P Global CSA 

The S&P Global CSA allows companies to benchmark their performance across a broad spectrum of industry-specific economic, environmental, and social criteria, all of which are increasingly important to sustainability-focused investors and critical to corporate performance. By assessing companies on their sustainability strategies, performance, and transparency, it serves as a key benchmark for corporate responsibility. Ipsen’s improved score not only strengthens our global reputation but also sends a clear message to the market about our unwavering commitment to embedding sustainable practices throughout the organization. 

Closing the Gaps 

Over the past year, Ipsen implemented an ambitious action plan aimed at closing gaps in our sustainability disclosures. This included the development of key Position Papers, Statements, and Disclosures, which are available on Ipsen.com here. Our high level of data availability—87% disclosure rate, well above the industry average—further underscores our commitment to transparency. 

Looking Forward 

This achievement is not the end of the journey, but a steppingstone toward even greater heights. We are continually pushing ourselves to set new benchmarks in sustainability. Together, as Generation Ipsen, we are shaping a more sustainable future—one milestone at a time.